The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s.
A significant stride in the realm of integrated medicine has been reported by Remepy, a pioneering startup, as its innovative…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…
Read More
Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Breakthrough in Ultrafast Imaging Captures Phase and Intensity Dynamics of Femtosecond Phenomena in Single Shot
Researchers at East China Normal University have announced the development of a pioneering imaging architecture capable of visualizing the microscopic…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read More
